Pfizer Debt to Equity Ratio 2010-2024 | PFE
Current and historical debt to equity ratio values for Pfizer (PFE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Pfizer debt/equity for the three months ending September 30, 2024 was 0.63.
| Pfizer Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-09-30 |
$126.92B |
$92.56B |
1.37 |
| 2024-06-30 |
$128.22B |
$87.98B |
1.46 |
| 2024-03-31 |
$128.54B |
$92.56B |
1.39 |
| 2023-12-31 |
$137.21B |
$89.29B |
1.54 |
| 2023-09-30 |
$117.82B |
$97.20B |
1.21 |
| 2023-06-30 |
$120.88B |
$99.29B |
1.22 |
| 2023-03-31 |
$94.38B |
$101.24B |
0.93 |
| 2022-12-31 |
$101.29B |
$95.92B |
1.06 |
| 2022-09-30 |
$102.46B |
$92.89B |
1.10 |
| 2022-06-30 |
$107.82B |
$87.47B |
1.23 |
| 2022-03-31 |
$101.16B |
$82.69B |
1.22 |
| 2021-12-31 |
$104.01B |
$77.46B |
1.34 |
| 2021-09-30 |
$103.22B |
$75.97B |
1.36 |
| 2021-06-30 |
$99.61B |
$70.32B |
1.42 |
| 2021-03-31 |
$89.95B |
$68.87B |
1.31 |
| 2020-12-31 |
$90.76B |
$63.47B |
1.43 |
| 2020-09-30 |
$113.49B |
$65.50B |
1.73 |
| 2020-06-30 |
$113.37B |
$64.56B |
1.76 |
| 2020-03-31 |
$101.00B |
$65.34B |
1.55 |
| 2019-12-31 |
$104.15B |
$63.45B |
1.64 |
| 2019-09-30 |
$105.05B |
$65.40B |
1.61 |
| 2019-06-30 |
$96.27B |
$59.92B |
1.61 |
| 2019-03-31 |
$96.26B |
$59.16B |
1.63 |
| 2018-12-31 |
$95.66B |
$63.76B |
1.50 |
| 2018-09-30 |
$96.17B |
$71.66B |
1.34 |
| 2018-06-30 |
$94.86B |
$70.12B |
1.35 |
| 2018-03-31 |
$94.07B |
$70.54B |
1.33 |
| 2017-12-31 |
$100.14B |
$71.66B |
1.40 |
| 2017-09-30 |
$111.04B |
$61.11B |
1.82 |
| 2017-06-30 |
$109.86B |
$58.69B |
1.87 |
| 2017-03-31 |
$110.04B |
$58.75B |
1.87 |
| 2016-12-31 |
$111.78B |
$59.84B |
1.87 |
| 2016-09-30 |
$114.83B |
$63.60B |
1.81 |
| 2016-06-30 |
$107.59B |
$63.07B |
1.71 |
| 2016-03-31 |
$99.58B |
$63.35B |
1.57 |
| 2015-12-31 |
$102.38B |
$65.00B |
1.58 |
| 2015-09-30 |
$103.74B |
$67.12B |
1.55 |
| 2015-06-30 |
$93.70B |
$67.18B |
1.40 |
| 2015-03-31 |
$93.05B |
$67.59B |
1.38 |
| 2014-12-31 |
$95.94B |
$71.62B |
1.34 |
| 2014-09-30 |
$93.06B |
$78.31B |
1.19 |
| 2014-06-30 |
$95.66B |
$76.96B |
1.24 |
| 2014-03-31 |
$93.74B |
$78.07B |
1.20 |
| 2013-12-31 |
$95.48B |
$76.62B |
1.25 |
| 2013-09-30 |
$97.17B |
$78.35B |
1.24 |
| 2013-06-30 |
$100.36B |
$78.98B |
1.27 |
| 2013-03-31 |
$104.57B |
$82.83B |
1.26 |
| 2012-12-31 |
$104.12B |
$81.68B |
1.28 |
| 2012-09-30 |
$100.49B |
$82.12B |
1.22 |
| 2012-06-30 |
$102.88B |
$79.96B |
1.29 |
| 2012-03-31 |
$102.01B |
$83.68B |
1.22 |
| 2011-12-31 |
$105.38B |
$82.62B |
1.28 |
| 2011-09-30 |
$105.60B |
$90.53B |
1.17 |
| 2011-06-30 |
$106.94B |
$88.96B |
1.20 |
| 2011-03-31 |
$104.42B |
$90.53B |
1.15 |
| 2010-12-31 |
$106.75B |
$88.27B |
1.21 |
| 2010-09-30 |
$103.35B |
$88.07B |
1.17 |
| 2010-06-30 |
$104.19B |
$86.88B |
1.20 |
| 2010-03-31 |
$105.03B |
$90.08B |
1.17 |
| 2009-12-31 |
$122.50B |
$90.45B |
1.35 |
| 2009-09-30 |
$75.04B |
$66.25B |
1.13 |
| 2009-06-30 |
$76.10B |
$63.24B |
1.20 |
| 2009-03-31 |
$62.49B |
$60.44B |
1.03 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$151.535B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
